Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations
Authors
Keywords
-
Journal
PROSTATE CANCER AND PROSTATIC DISEASES
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-03-05
DOI
10.1038/s41391-020-0217-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Polycomb Group Proteins EZH2 and EED Directly Regulate Androgen Receptor in Advanced Prostate Cancer
- (2019) Qipeng Liu et al. INTERNATIONAL JOURNAL OF CANCER
- Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer
- (2019) Xin Han et al. JOURNAL OF MEDICINAL CHEMISTRY
- Effect of Monoamine oxidase A (MAOA) inhibitors on androgen‐sensitive and castration‐resistant prostate cancer cells
- (2019) Shikha Gaur et al. PROSTATE
- Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
- (2019) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial
- (2019) Bertrand Tombal et al. LANCET ONCOLOGY
- Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study
- (2019) Andrew J. Armstrong et al. JOURNAL OF CLINICAL ONCOLOGY
- ARV-110: An oral androgen receptor PROTAC degrader for prostate cancer.
- (2019) Taavi Neklesa et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification of a chemical modulator of EZH2-mediated silencing by cell-based high-throughput screening assay
- (2019) Akihiro Murashima et al. JOURNAL OF BIOCHEMISTRY
- ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer
- (2019) Laura Cato et al. CANCER CELL
- Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer
- (2019) Adam Sharp et al. EUROPEAN UROLOGY
- Preclinical investigation of a small molecule inhibitor of p300/CBP reveals efficacy in patient-derived prostate tumor explants.
- (2019) Lisa Butler et al. JOURNAL OF CLINICAL ONCOLOGY
- Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial
- (2019) Karim Fizazi et al. LANCET ONCOLOGY
- The novel BET‐CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild‐type prostate cancer
- (2019) Yuqian Yan et al. EMBO Molecular Medicine
- Androgen Receptor Modulation Optimized for Response—Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7–expressing Metastatic Castration-resistant Prostate Cancer
- (2019) Mary-Ellen Taplin et al. EUROPEAN UROLOGY
- Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer
- (2019) E J Small et al. ANNALS OF ONCOLOGY
- Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial
- (2019) Daniel J Khalaf et al. LANCET ONCOLOGY
- Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases
- (2018) Heini M. L. Kallio et al. BRITISH JOURNAL OF CANCER
- Androgen receptor (AR) degradation enhancer ASC-J9 ® in an FDA-approved formulated solution suppresses castration resistant prostate cancer cell growth
- (2018) Max A. Cheng et al. CANCER LETTERS
- Targeting the Hsp40/Hsp70 Chaperone Axis as a Novel Strategy to Treat Castration-Resistant Prostate Cancer
- (2018) Michael A. Moses et al. CANCER RESEARCH
- Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC)
- (2018) Jonathan Welti et al. CLINICAL CANCER RESEARCH
- In Situ Detection and Quantification of AR-V7, AR-FL, PSA, andKRASPoint Mutations in Circulating Tumor Cells
- (2018) Amin El-Heliebi et al. CLINICAL CHEMISTRY
- Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer
- (2018) Yezi Zhu et al. EUROPEAN UROLOGY
- Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting
- (2018) Jun Luo et al. EUROPEAN UROLOGY
- The retinamide VNLG-152 inhibits f-AR/AR-V7 and MNK-eIF4E signaling pathways to suppress EMT and castration-resistant prostate cancer xenograft growth
- (2018) Vidya P. Ramamurthy et al. FEBS Journal
- The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Nonmetastatic Castration Resistant Prostate Cancer
- (2018) Charles J. Ryan et al. JOURNAL OF UROLOGY
- Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study
- (2018) Benjamin A Teply et al. LANCET ONCOLOGY
- Therapeutic Potential of Leelamine, a Novel Inhibitor of Androgen Receptor and Castration-Resistant Prostate Cancer
- (2018) Krishna B Singh et al. MOLECULAR CANCER THERAPEUTICS
- Gene Expression Analysis of Immunomagnetically Enriched Circulating Tumor Cell Fraction in Castration-Resistant Prostate Cancer
- (2018) Markéta Škereňová et al. Molecular Diagnosis & Therapy
- Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
- (2018) Maha Hussain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
- (2018) Matthew R. Smith et al. NEW ENGLAND JOURNAL OF MEDICINE
- Androgen receptor splice variants bind to constitutively open chromatin and promote abiraterone-resistant growth of prostate cancer
- (2018) Yundong He et al. NUCLEIC ACIDS RESEARCH
- Histone demethylase JMJD1A promotes alternative splicing of AR variant 7 (AR-V7) in prostate cancer cells
- (2018) Lingling Fan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13
- (2018) Zhong Chen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Inhibition of androgen receptor transactivation function by adenovirus type 12 E1A undermines prostate cancer cell survival
- (2018) Dawei Li et al. PROSTATE
- An RNA-Based Digital Circulating Tumor Cell Signature Is Predictive of Drug Response and Early Dissemination in Prostate Cancer
- (2018) David T. Miyamoto et al. Cancer Discovery
- Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer
- (2018) Howard I. Scher et al. JAMA Oncology
- An intravascular magnetic wire for the high-throughput retrieval of circulating tumour cells in vivo
- (2018) Ophir Vermesh et al. Nature Biomedical Engineering
- Small molecule-induced degradation of the full length and V7 truncated variant forms of human androgen receptor
- (2018) Kush Dalal et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Expression pattern of androgen receptor and AR-V7 in androgen deprivation therapy naïve salivary duct carcinomas
- (2018) Richard K. Yang et al. HUMAN PATHOLOGY
- ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer
- (2018) Ling Cai et al. MOLECULAR CELL
- Identification of an oncogenic network with prognostic and therapeutic value in prostate cancer
- (2018) Fiorella Magani et al. Molecular Systems Biology
- Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer
- (2018) Adam Sharp et al. JOURNAL OF CLINICAL INVESTIGATION
- New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity
- (2018) Dong-Jin Hwang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer
- (2018) Giorgia Zadra et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Riluzole induces AR degradation via endoplasmic reticulum stress pathway in androgen‐dependent and castration‐resistant prostate cancer cells
- (2018) Kristine M. Wadosky et al. PROSTATE
- Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator
- (2018) Jung Kim et al. Cell Reports
- Androgen Receptor Splice Variant 7 Drives the Growth of Castration Resistant Prostate Cancer without Being Involved in the Efficacy of Taxane Chemotherapy
- (2018) Yasuomi Shimizu et al. Journal of Clinical Medicine
- Androgen Receptor Regulation of Local Growth Hormone in Prostate Cancer Cells
- (2017) M. Victoria Recouvreux et al. ENDOCRINOLOGY
- Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9 ® to Suppress Enzalutamide-resistant Prostate Cancer Progression
- (2017) Ronghao Wang et al. EUROPEAN UROLOGY
- Comprehensive Profiling of the Androgen Receptor in Liquid Biopsies from Castration-resistant Prostate Cancer Reveals Novel Intra-AR Structural Variation and Splice Variant Expression Patterns
- (2017) Bram De Laere et al. EUROPEAN UROLOGY
- Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer
- (2017) Howard I. Scher et al. EUROPEAN UROLOGY
- AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide
- (2017) Anna Katharina Seitz et al. EUROPEAN UROLOGY
- The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients
- (2017) Marzia Del Re et al. EUROPEAN UROLOGY
- Developing new targeting strategy for androgen receptor variants in castration resistant prostate cancer
- (2017) Bin Wang et al. INTERNATIONAL JOURNAL OF CANCER
- Analytical Validation of Androgen Receptor Splice Variant 7 Detection in a Clinical Laboratory Improvement Amendments (CLIA) Laboratory Setting
- (2017) Parvez M. Lokhandwala et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate
- (2017) Tilman Todenhöfer et al. JOURNAL OF UROLOGY
- Androgen-receptor splice variant-7-positive prostate cancer: a novel molecular subtype with markedly worse androgen-deprivation therapy outcomes in newly diagnosed patients
- (2017) Heng Li et al. MODERN PATHOLOGY
- Aurora Kinase A Promotes AR Degradation via the E3 Ligase CHIP
- (2017) Sukumar Sarkar et al. MOLECULAR CANCER RESEARCH
- CDK4/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPC
- (2017) James P. Stice et al. MOLECULAR CANCER RESEARCH
- 6BIO Enhances Oligonucleotide Activity in Cells: A Potential Combinatorial Anti-androgen Receptor Therapy in Prostate Cancer Cells
- (2017) Xiaowei Zhang et al. MOLECULAR THERAPY
- Prostate cancer–associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4
- (2017) Xiangpeng Dai et al. NATURE MEDICINE
- Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT–mTORC1 activation
- (2017) Pingzhao Zhang et al. NATURE MEDICINE
- Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
- (2017) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
- (2017) Nicholas D. James et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeted protein degradation by PROTACs
- (2017) Taavi K. Neklesa et al. PHARMACOLOGY & THERAPEUTICS
- Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer
- (2017) Abigail B. McLeod et al. PROSTATE
- Glycogen synthase kinase-3 inhibitors suppress the AR-V7-mediated transcription and selectively inhibit cell growth in AR-V7-positive prostate cancer cells
- (2017) Daisuke Nakata et al. PROSTATE
- Minnelide Inhibits Androgen Dependent, Castration Resistant Prostate Cancer Growth by Decreasing Expression of Androgen Receptor Full Length and Splice Variants
- (2017) Sumit Isharwal et al. PROSTATE
- Development of cell-penetrating bispecific antibodies targeting the N-terminal domain of androgen receptor for prostate cancer therapy†
- (2017) Nancy L Goicochea et al. PROTEIN ENGINEERING DESIGN & SELECTION
- Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance
- (2017) Sheng Yu Ku et al. SCIENCE
- Repression of BET activity sensitizes homologous recombination–proficient cancers to PARP inhibition
- (2017) Lu Yang et al. Science Translational Medicine
- The expression of AURKA is androgen regulated in castration-resistant prostate cancer
- (2017) Kati Kivinummi et al. Scientific Reports
- Targeting NF-kappa B Signaling by Artesunate Restores Sensitivity of Castrate-Resistant Prostate Cancer Cells to Antiandrogens
- (2017) Jessica J. Nunes et al. NEOPLASIA
- Aurora A regulates expression of AR-V7 in models of castrate resistant prostate cancer
- (2017) Dominic Jones et al. Scientific Reports
- Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer Cells
- (2016) R. Ferraldeschi et al. CANCER RESEARCH
- Branched Chain RNA In Situ Hybridization for Androgen Receptor Splice Variant AR-V7 as a Prognostic Biomarker for Metastatic Castration-Sensitive Prostate Cancer
- (2016) Philip J. Saylor et al. CLINICAL CANCER RESEARCH
- Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer
- (2016) Y. C. Yang et al. CLINICAL CANCER RESEARCH
- Analytic Validation of RNA In Situ Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer
- (2016) L. B. Guedes et al. CLINICAL CANCER RESEARCH
- Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer
- (2016) Jonathan Welti et al. EUROPEAN UROLOGY
- Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort
- (2016) Matthew R. Smith et al. EUROPEAN UROLOGY
- The marine triterpene glycoside frondoside A exhibits activity in vitro and in vivo in prostate cancer
- (2016) Sergey A. Dyshlovoy et al. INTERNATIONAL JOURNAL OF CANCER
- The Amino-terminal Domain of the Androgen Receptor Co-opts Extracellular Signal-regulated Kinase (ERK) Docking Sites in ELK1 Protein to Induce Sustained Gene Activation That Supports Prostate Cancer Cell Growth
- (2016) Rayna Rosati et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial
- (2016) David F. Penson et al. JOURNAL OF CLINICAL ONCOLOGY
- Potential Role for YB-1 in Castration-Resistant Prostate Cancer and Resistance to Enzalutamide Through the Androgen Receptor V7
- (2016) Masaki Shiota et al. JNCI-Journal of the National Cancer Institute
- A Whole Blood Assay for AR-V7 and ARv567es in Patients with Prostate Cancer
- (2016) Xichun Liu et al. JOURNAL OF UROLOGY
- Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity
- (2016) Thirupandiyur S. Udayakumar et al. MOLECULAR CANCER THERAPEUTICS
- ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer
- (2016) Junjian Wang et al. NATURE MEDICINE
- PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
- (2016) Kanak Raina et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model
- (2016) Daisuke Nakata et al. PROSTATE
- High-Content Screening Identifies Src Family Kinases as Potential Regulators of AR-V7 Expression and Androgen-Independent Cell Growth
- (2016) Adam T. Szafran et al. PROSTATE
- Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting
- (2016) E S Antonarakis et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Identification of Novel Steroidal Androgen Receptor Degrading Agents Inspired by Galeterone 3β-Imidazole Carbamate
- (2016) Puranik Purushottamachar et al. ACS Medicinal Chemistry Letters
- Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer
- (2016) Christine Henzler et al. Nature Communications
- Potential Role for YB-1 in Castration-Resistant Prostate Cancer and Resistance to Enzalutamide Through the Androgen Receptor V7
- (2016) Masaki Shiota et al. JNCI-Journal of the National Cancer Institute
- CUDC-101, a Novel Inhibitor of Full-Length Androgen Receptor (flAR) and Androgen Receptor Variant 7 (AR-V7) Activity: Mechanism of Action and In Vivo Efficacy
- (2016) Huiying Sun et al. Hormones & Cancer
- The Use of a New CellCollector to Isolate Circulating Tumor Cells from the Blood of Patients with Different Stages of Prostate Cancer and Clinical Outcomes - A Proof-of-Concept Study
- (2016) Gerit Theil et al. PLoS One
- Regulation of PCGEM1 by p54/nrb in prostate cancer
- (2016) Tsui-Ting Ho et al. Scientific Reports
- Androgen Receptor Splice Variants Dimerize to Transactivate Target Genes
- (2015) D. Xu et al. CANCER RESEARCH
- Integrative Clinical Genomics of Advanced Prostate Cancer
- (2015) Dan Robinson et al. CELL
- The Molecular Taxonomy of Primary Prostate Cancer
- (2015) Adam Abeshouse et al. CELL
- Androgen receptor modulates Foxp3 expression in CD4+CD25+Foxp3+ regulatory T-cells
- (2015) Magdalena Walecki et al. MOLECULAR BIOLOGY OF THE CELL
- NF- B2/p52:c-Myc:hnRNPA1 Pathway Regulates Expression of Androgen Receptor Splice Variants and Enzalutamide Sensitivity in Prostate Cancer
- (2015) N. Nadiminty et al. MOLECULAR CANCER THERAPEUTICS
- Regulation of c-Myc expression by the histone demethylase JMJD1A is essential for prostate cancer cell growth and survival
- (2015) L Fan et al. ONCOGENE
- Lin28 induces resistance to anti-androgens via promotion of AR splice variant generation
- (2015) Ramakumar Tummala et al. PROSTATE
- Simultaneous targeting of androgen receptor (AR) and MAPK-interacting kinases (MNKs) by novel retinamides inhibits growth of human prostate cancer cell lines
- (2015) Vidya P. Ramamurthy et al. Oncotarget
- EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer
- (2015) Lucas J. Brand et al. Oncotarget
- Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
- (2015) Emmanuel S. Antonarakis et al. JAMA Oncology
- Rapid Induction of Androgen Receptor Splice Variants by Androgen Deprivation in Prostate Cancer
- (2014) Z. Yu et al. CLINICAL CANCER RESEARCH
- Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer
- (2014) Kathryn E Ware et al. ENDOCRINE-RELATED CANCER
- Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer
- (2014) Irfan A. Asangani et al. NATURE
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Characterization of a New Class of Androgen Receptor Antagonists with Potential Therapeutic Application in Advanced Prostate Cancer
- (2013) Huifang Li et al. MOLECULAR CANCER THERAPEUTICS
- Mechanisms of the androgen receptor splicing in prostate cancer cells
- (2013) L L Liu et al. ONCOGENE
- HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner
- (2013) M. Malvaez et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- New Therapeutic Approach to Suppress Castration-Resistant Prostate Cancer Using ASC-J9 via Targeting Androgen Receptor in Selective Prostate Cells
- (2012) Kuo-Pao Lai et al. AMERICAN JOURNAL OF PATHOLOGY
- Distinct Transcriptional Programs Mediated by the Ligand-Dependent Full-Length Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer
- (2012) R. Hu et al. CANCER RESEARCH
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
- (2012) Charles J. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent
- (2012) K. Xu et al. SCIENCE
- A Preclinical Evaluation of Minnelide as a Therapeutic Agent Against Pancreatic Cancer
- (2012) R. Chugh et al. Science Translational Medicine
- Androgen Receptor Gene Expression in Prostate Cancer Is Directly Suppressed by the Androgen Receptor Through Recruitment of Lysine-Specific Demethylase 1
- (2011) Changmeng Cai et al. CANCER CELL
- Selective Roles for cAMP Response Element-binding Protein Binding Protein and p300 Protein as Coregulators for Androgen-regulated Gene Expression in Advanced Prostate Cancer Cells
- (2011) Irina Ianculescu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- XPB, a subunit of TFIIH, is a target of the natural product triptolide
- (2011) Denis V Titov et al. Nature Chemical Biology
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- CUDC-101, a Multitargeted Inhibitor of Histone Deacetylase, Epidermal Growth Factor Receptor, and Human Epidermal Growth Factor Receptor 2, Exerts Potent Anticancer Activity
- (2010) Cheng-Jung Lai et al. CANCER RESEARCH
- Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor
- (2010) P. A. Watson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Steroid Hormone Receptors in Prostate Cancer: A Hard Habit to Break?
- (2009) Gerhardt Attard et al. CANCER CELL
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
- (2009) C. Tran et al. SCIENCE
- Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer
- (2008) R. Hu et al. CANCER RESEARCH
- Targeting the androgen receptor pathway in prostate cancer
- (2008) Yu Chen et al. CURRENT OPINION IN PHARMACOLOGY
- Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer
- (2008) A Rodriguez-Gonzalez et al. ONCOGENE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started